Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia
clinical isolates
Authors
Keywords
-
Journal
MOLECULAR MICROBIOLOGY
Volume 106, Issue 3, Pages 492-504
Publisher
Wiley
Online
2017-09-06
DOI
10.1111/mmi.13831
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-β-Lactamases and Penicillin-Binding Proteins
- (2016) Andrew M. King et al. ACS Chemical Biology
- Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates
- (2016) Karina Calvopiña et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient
- (2016) Maria F. Mojica et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interaction of Avibactam with Class B Metallo-β-Lactamases
- (2016) Martine I. Abboud et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
- (2016) David Yuxin Wang et al. Future Medicinal Chemistry
- Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition
- (2016) Hwanho Choi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates
- (2016) Jürgen Brem et al. Nature Communications
- Diffraction-geometry refinement in theDIALSframework
- (2016) David G. Waterman et al. Acta Crystallographica Section D-Structural Biology
- High-level quinolone resistance is associated with the overexpression of smeVWX in Stenotrophomonas maltophilia clinical isolates
- (2015) G. García-León et al. CLINICAL MICROBIOLOGY AND INFECTION
- Exploring the Mechanism of β-Lactam Ring Protonation in the Class A β-lactamase Acylation Mechanism Using Neutron and X-ray Crystallography
- (2015) Venu Gopal Vandavasi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
- (2015) Scott J. Hecker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition
- (2015) Dustin T. King et al. ACS Infectious Diseases
- Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study
- (2015) Nikhil P. Krishnan et al. PLoS One
- Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48
- (2014) Sushmita D. Lahiri et al. ACS Chemical Biology
- Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance
- (2014) S. D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
- (2014) Timothy A. Blizzard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe
- (2014) Ann Versporten et al. LANCET INFECTIOUS DISEASES
- Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
- (2014) Thomas P Van Boeckel et al. LANCET INFECTIOUS DISEASES
- New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
- (2013) Sarah M. Drawz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Involvement of Mutation inampDI,mrcA, and at Least One Additional Gene in β-Lactamase Hyperproduction in Stenotrophomonas maltophilia
- (2013) Asmaa Talfan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
- (2013) Sushmita D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The ABCD’s of β-lactamase nomenclature
- (2013) Karen Bush JOURNAL OF INFECTION AND CHEMOTHERAPY
- Assay Platform for Clinically Relevant Metallo-β-lactamases
- (2013) Sander S. van Berkel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Coordinate Hyperproduction of SmeZ and SmeJK Efflux Pumps Extends Drug Resistance in Stenotrophomonas maltophilia
- (2012) Virginia C. Gould et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis
- (2012) Hua Xu et al. BIOCHEMISTRY
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
- (2012) J. S. Brooke CLINICAL MICROBIOLOGY REVIEWS
- The Basis for Carbapenem Hydrolysis by Class A β-Lactamases: A Combined Investigation using Crystallography and Simulations
- (2012) Fátima Fonseca et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overview of theCCP4 suite and current developments
- (2011) Martyn D. Winn et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- XDS
- (2010) Wolfgang Kabsch ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Three Decades of -Lactamase Inhibitors
- (2010) S. M. Drawz et al. CLINICAL MICROBIOLOGY REVIEWS
- The antibiotics market
- (2010) Bashar Hamad NATURE REVIEWS DRUG DISCOVERY
- Challenging and emerging pathogens in cystic fibrosis
- (2010) A.M.M. de Vrankrijker et al. Paediatric Respiratory Reviews
- electronic Ligand Builder and Optimization Workbench(eLBOW): a tool for ligand coordinate and restraint generation
- (2009) Nigel W. Moriarty et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- MolProbity: all-atom structure validation for macromolecular crystallography
- (2009) Vincent B. Chen et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Structural and Biochemical Characterization of the Interaction between KPC-2 β-Lactamase and β-Lactamase Inhibitor Protein,
- (2009) Melinda S. Hanes et al. BIOCHEMISTRY
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
- (2009) T. Stachyra et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The MORPHEUS protein crystallization screen
- (2009) Fabrice Gorrec JOURNAL OF APPLIED CRYSTALLOGRAPHY
- Stenotrophomonas maltophilia: an emerging opportunist human pathogen
- (2009) W John Looney et al. LANCET INFECTIOUS DISEASES
- The versatility and adaptation of bacteria from the genus Stenotrophomonas
- (2009) Robert P. Ryan et al. NATURE REVIEWS MICROBIOLOGY
- Induction of L1 and L2 -Lactamase Production in Stenotrophomonas maltophilia Is Dependent on an AmpR-Type Regulator
- (2008) A. Okazaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants
- (2008) Lisa C Crossman et al. GENOME BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started